M&A - Enovis CORP

Form Type: 10-Q

Filing Date: 2025-05-08

Corporate Action: Acquisition

Type: New

Accession Number: 000142080025000018

Filing Summary: Enovis Corporation's quarterly report for the period ended April 4, 2025, reveals key financial metrics indicating a net sales increase to $558.8 million compared to $516.3 million in the same period last year, driven by growth in both the Prevention & Recovery and Reconstructive segments. The report shows a net loss from continuing operations of $55.6 million, a significant improvement from a net loss of $71.8 million the previous year. The company completed five bolt-on acquisitions during the first quarter of 2025 at a total consideration of $30.0 million, enhancing product offerings in both segments. The operating loss of $46.8 million reflects substantial investments in research and development and ongoing operational challenges. Total assets grew to $4.88 billion, while current liabilities were recorded at approximately $477.4 million. Cash and cash equivalents decreased to $38.5 million, and total equity rose to $2.62 billion, indicating a stable financial position despite recent operational losses.

Form Type: 424B7

Filing Date: 2025-01-28

Corporate Action: Acquisition

Type: Update

Accession Number: 000119312525013853

Filing Summary: This prospectus supplement relates to the resale of up to 971,343 shares of common stock of Enovis Corporation by the Selling Stockholder, issued as part of an acquisition of LimaCorporate S.p.A. through a Share Purchase Agreement dated September 22, 2023. The common stock was registered for resale following a Registration Rights Agreement dated January 3, 2024. The first tranche of shares (971,343) was issued on July 16, 2024, and the second tranche (971,343) was issued on January 15, 2025. Enovis Corporation will not receive any proceeds from the sale of these shares, which may be sold at varying prices based on market conditions. As of January 27, 2025, the closing price of the common stock was $47.67.

Form Type: 8-K

Filing Date: 2025-01-28

Corporate Action: Acquisition

Type: New

Accession Number: 000119312525013860

Filing Summary: On January 28, 2025, Enovis Corporation filed a prospectus supplement with the SEC covering the resale of up to 971,343 shares of common stock held by Emil Holding II S.à r.l., related to the acquisition of LimaCorporate S.p.A. The shares were issued as part of the consideration in the acquisition, which involved the issuance of up to an aggregate of 1,942,686 shares in two equal tranches. The first tranche was issued to Emil on July 16, 2024, while the second tranche was issued on January 15, 2025. The filing also includes a legal opinion from Latham & Watkins LLP regarding the legality of the securities.